Clinical trials: Psychotic Symptoms
Obesity, Overweight
Interactive Obesity Treatment Approach for Obesity Prevention in Adults With Early Serious Mental Illness: iOTA-SMI
Using a design-for-dissemination approach, this application proposes to use combined methods to adapt and pilot test an interactive obesity treatment approach (iOTA) for obesity prevention in early serious mental illness (eSMI)…
- Conditions
- Obesity, Overweight, Severe Mental Disorder
- Trial name
- iOTA-eSMI (NCT03980743)
- Testing
- iOTA text messaging intervention, Health Education text messaging intervention
- Where
- 2 sites in United States
- Volunteers
- 51 people
- Sponsor
- Washington University School of Medicine
Schizophrenia, Substance Use
Effects of Physical Activity in Psychosis
Physical health problems are common in schizophrenia with a two- to three-fold increased morbidity and mortality rate, resulting in a 20 years reduction in life expectancy.
- Trial name
- EPHAPS (NCT02205684)
- Testing
- Computer game skills training, Physical activity
- Volunteers
- 126 people
- Sponsor
- Sykehuset i Vestfold HF
Schizophrenia, Schizoaffective Disorder
Adjunctive Treatment for Decreasing Symptoms of Schizophrenia
This study will determine the effectiveness of treatment with glycine or d-cycloserine in addition to a normal antipsychotic regimen in improving negative symptoms and cognitive impairments in patients with schizophrenia.
- Trial name
- NCT00222235
- Testing
- d-cycloserine, glycine
- Where
- 5 sites in United States, Israel
- Volunteers
- 240 people
- Sponsor
- University of Maryland, Baltimore
None Volunteer
An Investigation of Mechanisms That Underly Paranoia in Behaviour and Brain That Can Inform Clinical Diagnoses That Include Paranoid Symptoms.
The study team is studying how delta-9-tetrahydrocannabinol (THC) - the component of cannabis that is responsible for "getting people feeling high" - influences how people think about the behaviour of others and a variety of…
- Trial name
- NCT07878130
- Testing
- Low-dose THC administration via IV, High-Dose THC administration via IV, Saline administration via IV
- Where
- United Kingdom
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- King's College London
Psychosis
Determining the Role of Social Reward Learning in Social Anhedonia
This is a clinical trial study that aims to evaluate the specificity of the relationship between reduced sensitivity to social reward and social anhedonia at both behavioral and neural levels.
- Trial name
- SAMI (NCT05617898)
- Testing
- Motivational Interviewing, Nutrition Didactic Training
- Where
- 2 sites in United States
- Volunteers
- 152 people
- Sponsor
- University of Alabama at Birmingham
Psychosis, Suicide
Targeting Emotion Dysregulation to Reduce Suicide in People With Psychosis
People with psychotic disorders are excluded from most suicide-focused clinical trials despite incredibly high rates of completed suicide, and interventions that have been tested for this population have shown limited impact on…
- Trial name
- NCT05440214
- Testing
- Dialectical Behavior Therapy Skills Training
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- University of Maryland, Baltimore
Schizophrenia
Reboxetine and Citalopram as an Adjunct Treatment to Second Generation Antipsychotics in the Treatment of Negative Symptoms of Schizophrenia
Main objective: To assess the efficacy of two antidepressants of different pharmacological families: citalopram (Selective serotonin reuptake inhibitors, SSRI) and reboxetine (Norepinephrine Reuptake inhibitor, NRI) as adjunct…
- Trial name
- NCT01300364
- Testing
- Reboxetine, citalopram (SSRI)
- Where
- Spain
- Volunteers
- 249 people
- Sponsor
- Fundació Sant Joan de Déu
Schizophrenia
Impact of Inflammation on Reward Circuits, Motivational Deficits and Negative Symptoms in Schizophrenia
This study will recruit persons with schizophrenia or schizoaffective disorder and will use an oral glucose tolerance test to test the hypothesis that insulin resistance drives inflammation.
- Trial name
- NCT03818516
- Testing
- Oral Glucose Tolerance Test (OGTT)
- Where
- 6 sites in United States
- Volunteers
- 12 people
- Sponsor
- Emory University
Schizophrenia / Schizoaffective Disorder, First Episode Psychosis (FEP)
French Minds Cohort: a French Longitudinal and Multimodal Cohort of Patients With Major Mood Disorders, Psychotic Disorders, Autism Spectrum Disorders, and Healthy Controls
The goal of this study is to learn whether people living with severe psychiatric disorders can be grouped into more homogeneous subgroups, across usual diagnostic categories, based on two key dimensions: social withdrawal and…
- Conditions
- Schizophrenia / Schizoaffective Disorder, First Episode Psychosis (FEP), Bipolar Disorder (BD), Major Depressive Disorder (MDD
- Trial name
- FRENCH-MINDS (NCT07881016)
- Testing
- 3T Brain MRI, Biological Sampling, Clinical, Cognitive and Digital Assessments
- Where
- 17 sites in France
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Fondation FondaMental
Depression, Catatonia
Survey on Pre-ECT Evaluation and ECT Application
The aim of this study is to identify specifics of pre-ECT assessments and ECT application in European psychiatric services. We will engage European centres that provide ECT for psychiatric patients and for psychiatric…
- Conditions
- Depression, Catatonia, Schizophrenia, Schizoaffective Disorder
- Trial name
- NCT04335916
- Where
- Croatia
- Volunteers
- 30 people
- Sponsor
- Klinički Bolnički Centar Zagreb
Schizophrenia, Schizoaffective Disorder
A Definitive Estrogen Patch Study (ADEPT)
OBJECTIVE: To test the use of adjunctive estrogen in a 8 week, three-arm, double-blind, placebo-controlled study in the treatment of psychotic symptoms in women with schizophrenia.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder(Not in Manic Phase)
- Trial name
- NCT00357006
- Testing
- Estradiol
- Where
- Australia
- Volunteers
- 180 people
- Sponsor
- The Alfred
Psychotic Disorders, Schizophrenia
Virtual Cognitive Behavioural Therapy for Psychosis
Participants with schizophrenia-spectrum disorders who are experiencing active symptoms of psychosis will randomized to either receive 6 months of individual cognitive behavioural therapy for psychosis or to receive treatment as…
- Trial name
- NCT04752449
- Testing
- Virtual Cognitive Behavioural Therapy for Psychosis
- Where
- Canada
- Volunteers
- 70 people
- Sponsor
- University of Toronto
Alzheimer Disease
Valproate in Dementia (VALID)
The purpose of this trial is to demonstrate whether valproate therapy delays the emergence of agitation and/or psychosis in outpatients with probable Alzheimer's disease (AD) who have not experienced agitation and psychosis in…
- Trial name
- NCT00071721
- Testing
- Valproate
- Where
- 46 sites in United States
- Volunteers
- 313 people
- Sponsor
- Alzheimer's Disease Cooperative Study (ADCS)
Schizophrenia, Schizoaffective Disorder
Transcranial Current Stimulation as a Treatment for Auditory Hallucinations in Schizophrenia
Investigating the effect of non-invasive transcranial current stimulation on auditory hallucinations in patients with schizophrenia.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Auditory Hallucinations
- Trial name
- NCT01963676
- Testing
- tDCS
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- University of North Carolina, Chapel Hill
Mental Disorder, Metabolic Disturbance
Is Saxenda® a Viable Treatment of Obese Patients in Forensic Psychiatry?
An open-label, multi-centre, 26-weeks clinical feasibility study. The objective is to explore whether Saxenda could be a feasible choice in the treatment of overweight, obesity and weight-related medical problems, in patients…
- Conditions
- Mental Disorder, Metabolic Disturbance, Feasibility, Overweight and Obesity
- Trial name
- NCT04781998
- Testing
- liraglutide 3 mg (Saxenda®) once-daily
- Where
- Denmark
- Volunteers
- 24 people
- Sponsor
- Anders Fink-Jensen, MD, DMSci
Schizophrenia
Adjunctive Withania Somnifera (Ashwagandha) for Persistent Symptoms in People With Schizophrenia
To determine whether a standardized extract of Withania somnifera will reduce psychopathology scores (PANSS total score) in persons with schizophrenia.
- Trial name
- NCT03437668
- Testing
- WSE
- Where
- 2 sites in United States
- Volunteers
- 47 people
- Sponsor
- Chengappa, K.N. Roy, MD
Psychiatric Disorders (Diagnosis)
Contribution of Virtual Reality Eye Tracking in the Identification of Schizophrenia, Bipolar and Depression
Schizophrenia (SCZ), bipolar disorder (BP), and depression (DEP) are systematically associated with a severe impairment of the overall abilities of patients, which precludes them from functioning adequately in daily life.
- Trial name
- ReViPSY (NCT07057024)
- Testing
- Clinical and eye movements
- Where
- France
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Etablissement Public de Santé Barthélemy Durand
Auditory Hallucinations, Schizophrenia
Neuro-VR: Augmenting a Virtual Reality-based Therapy With Biofeedback for Auditory Hallucinations
The primary goal of this pilot study is to examine the feasibility and acceptability of augmenting a Virtual Reality-based intervention for treating auditory hallucinations in schizophrenia with electroencephalogram (EEG)-based…
- Trial name
- Neuro-VR (NCT06628323)
- Testing
- Virtual Reality-based Intervention employing Neurofeedback, Virtual Reality-based Intervention
- Where
- Denmark
- Volunteers
- 30 people
- Sponsor
- University Hospital Bispebjerg and Frederiksberg
Schizophrenia, Chronic Illness
Implementing Effective, Collaborative Care for Schizophrenia (EQUIP-2)
This project evaluates the implementation and effectiveness of a care model to improve treatment for schizophrenia within the context of diverse VA practices and priorities.
- Conditions
- Schizophrenia, Chronic Illness, Weight Gain, Psychotic Disorder
- Trial name
- EQUIP-2 (NCT00137280)
- Testing
- Collaborative Chronic Illness Care Model
- Where
- 8 sites in United States
- Volunteers
- 1,067 people
- Sponsor
- VA Office of Research and Development
Schizophrenia
Flexible-dose Long-term Extension Study of Lu AF11167 in Patients With Schizophrenia With Prominent Negative Symptoms
A study to evaluate the long-term safety and tolerability of flexible doses of Lu AF11167 in patients with schizophrenia during the 24-week treatment period
- Trial name
- NCT03929497
- Testing
- Lu AF11167
- Where
- 30 sites in Bulgaria, Estonia and 5 more
- Volunteers
- 96 people
- Sponsor
- H. Lundbeck A/S
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.